Key Takeaways
- • Mesirow Financial acquired Twenty20, a 355-unit luxury high-rise in Cambridge's life sciences hub, for $218 million, marking a significant institutional transaction in the Boston multifamily market.
- • CBRE's transaction team (Simon Butler, Biria St. John, John McLaughlin, and Brian Bowler) represented the institutional seller and procured the buyer, demonstrating cross-representation value in large-scale asset sales.
- • Twenty20 is a trophy-class 20-story residential tower built in 2015, featuring mixed unit types (studios through 4-bedrooms), averaging 807 square feet, with 186 garage parking spaces and 8,625 square feet of ground-floor retail within the 4.5 million-square-foot Cambridge Crossing mixed-use development.
- • The property benefits from proximity to major pharmaceutical and life sciences tenants (Sanofi, Bristol Myers Squibb, Philips, AbbVie, Astellas) occupying nearly two million square feet within the 43-acre Cambridge Crossing neighborhood, positioning it as a workforce-aligned residential asset.
- • The transaction reflects institutional capital's continued appetite for premium multifamily assets in innovation-driven markets with strong employment anchors and transit accessibility near Kendall Square.
Summary
Mesirow Financial completed the acquisition of Twenty20, a 355-unit luxury high-rise apartment community in East Cambridge, for $218 million. The transaction was arranged exclusively by CBRE, with a team led by Simon Butler, Biria St. John, John McLaughlin, and Brian Bowler representing both the institutional seller and procuring the buyer. According to supplemental market sources, the previous owner was PGIM, which held the asset for approximately a decade.
Twenty20 is a 20-story trophy-class residential tower originally constructed in 2015, positioned within the Cambridge Crossing mixed-use development—a 43-acre neighborhood encompassing 4.5 million square feet. The property comprises a diverse unit mix of studios, one-, two-, three-, and four-bedroom apartments, with an average unit size of 807 square feet. Residences feature nine-foot ceilings and direct access to 186 private garage parking spaces. The ground floor includes 8,625 square feet of retail space, anchoring the community's commercial component.
The asset's amenity package is designed to support institutional occupancy standards, including a rooftop terrace, a 3,000-square-foot fitness center with yoga sundeck, pet grooming facilities, full-time concierge services, club room, library, and secure bike storage. These features align with premium urban residential positioning and worker-retention objectives for the surrounding employment corridor.
Cambridge Crossing's strategic value derives from its concentration of life sciences and pharmaceutical employment. Major tenants occupying nearly two million square feet within the development include Sanofi, Bristol Myers Squibb, Philips, AbbVie, and Astellas Pharmaceuticals. The neighborhood also features more than 11 acres of open space, pedestrian infrastructure, and dedicated cycling facilities. The property provides direct access to multiple MBTA subway lines and is proximate to Kendall Square, a major U.S. innovation and biotech hub.
The $218 million valuation reflects institutional investor confidence in premium multifamily assets located within employment-dense, transit-accessible markets. This transaction underscores the continued capital flow toward high-quality residential assets serving knowledge-economy workers in established innovation clusters.
Twenty20 is a 20-story trophy-class residential tower originally constructed in 2015, positioned within the Cambridge Crossing mixed-use development—a 43-acre neighborhood encompassing 4.5 million square feet. The property comprises a diverse unit mix of studios, one-, two-, three-, and four-bedroom apartments, with an average unit size of 807 square feet. Residences feature nine-foot ceilings and direct access to 186 private garage parking spaces. The ground floor includes 8,625 square feet of retail space, anchoring the community's commercial component.
The asset's amenity package is designed to support institutional occupancy standards, including a rooftop terrace, a 3,000-square-foot fitness center with yoga sundeck, pet grooming facilities, full-time concierge services, club room, library, and secure bike storage. These features align with premium urban residential positioning and worker-retention objectives for the surrounding employment corridor.
Cambridge Crossing's strategic value derives from its concentration of life sciences and pharmaceutical employment. Major tenants occupying nearly two million square feet within the development include Sanofi, Bristol Myers Squibb, Philips, AbbVie, and Astellas Pharmaceuticals. The neighborhood also features more than 11 acres of open space, pedestrian infrastructure, and dedicated cycling facilities. The property provides direct access to multiple MBTA subway lines and is proximate to Kendall Square, a major U.S. innovation and biotech hub.
The $218 million valuation reflects institutional investor confidence in premium multifamily assets located within employment-dense, transit-accessible markets. This transaction underscores the continued capital flow toward high-quality residential assets serving knowledge-economy workers in established innovation clusters.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.